Retrospective Multicentre Study on the Impact of Neonatal Screening for Congenital Adrenal Hyperplasia in Italy

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Dec 6, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how effective neonatal screening is for a condition called Congenital Adrenal Hyperplasia (CAH) in newborns across various hospitals in Italy. CAH is a genetic disorder that affects the adrenal glands, which produce hormones that are important for growth and development. The study will gather information from babies who were screened for this condition between January 2006 and December 2019, as well as those diagnosed with CAH during that time.

To be eligible for this study, participants need to be newborns who were screened for CAH at the participating hospitals within the specified time frame and their families must provide consent for their involvement. Since this is a retrospective study, participants won’t need to do anything extra; researchers will review existing medical records to understand the impact of the screening. This study is important as it aims to improve early detection and treatment for CAH, ultimately helping better health outcomes for affected children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Neonatal who underwent neonatal screening for congenital adrenal hyperplasia between January 2006 and December 2019 at participating centres;
• • Patients diagnosed with Congenital Adrenal Hyperplasia;
• • Obtaining informed consent.
• Exclusion Criteria:
• • • None.